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Abstract: Recurrent glioblastoma multiforme (GBM), insensitive against most therapeutic 
interventions, has low response and survival rates. Temozolomide (TMZ) was approved for 
second-line therapy of recurrent anaplastic astrocytoma. However, TMZ therapy in GBM 
patients reveals properties such as reduced tolerability and inauspicious hemogram. The solu-
tion addressed here concerning GBM therapy consolidates and uses the potential of organic 
and peptide chemistry with molecular medicine. We enhanced the pharmacologic potency with 
simultaneous reduction of unwanted adverse reactions of the highly efﬁ  cient chemotherapeu-
tic TMZ. The TMZ connection to transporter molecules (TMZ-BioShuttle) was investigated, 
resulting in a much higher pharmacological effect in glioma cell lines and also with reduced 
dose rate. From this result we can conclude that a suitable chemistry could realize the ligation of 
pharmacologically active, but sensitive and highly unstable pharmaceutical ingredients without 
functional deprivation. The TMZ-BioShuttle dramatically enhanced the potential of TMZ for 
the treatment of brain tumors and is an attractive drug for combination chemotherapy.
Keywords: drug delivery, carrier molecules, facilitated transport, glioblastoma multiforme, 
temozolomide
Introduction
The Grade IV classiﬁ  cation of glioblastoma multiforme (GBM) means that these 
tumors grow aggressively and rapidly. The tumor entity GBM is considered one 
of the most aggressive and intractable cancers. Despite all treatments including 
neurosurgical resection followed by postoperative radiotherapy, the overall survival 
times of patients are unsatisfactory (Walker et al 1978). Therefore our aim is to use 
the potential for temozolomide (TMZ) to treat GBM by improving drug’s potency. 
The combination of the oral administration of TMZ with radiotherapy led to longer 
survival times (Combs et al 2005) by delaying tumor progression. Including simple 
oral application increased the interest in using TMZ to treat GBM (Osoba et al 2000). 
The action of TMZ (8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-
one) has been extensively studied, primarily in leukemia and lymphoma cells. TMZ 
is rapidly resorbed after oral application and spontaneously decomposes in aqueous 
solution at physiological pH to the cytotoxic methylating agent 5-(3-methyltriazen-
1-y1)imidazole-4-carboxamide (MTIC) (Tsang et al 1990). The cytotoxicity of TMZ 
appears to be mediated mainly through adduction of methyl groups to O6 positions of 
guanine (O6mG) in genomic DNA (Denny et al 1994) followed by recognition of this 
adduct by the mismatch repair system (MMR), which mispairs with thymine during 
the next cycle of DNA replication.
The half-life of TMZ (Riccardi et al 2003) in plasma and non-target-gene-speciﬁ  c 
alkylating mode of action can result in undesired adverse reactions which then hamper Drug Design, Development and Therapy 2008:2 290
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the therapeutic outcome efﬁ  ciency. For this reason new 
TMZ-derivatives were designed. The use of the peptide-
based nuclear localization sequence (NLS) (Braun et al 2002; 
Heckl et al 2002), which leads to an active nuclear targeting, 
could minimize existing handicaps. Because of their higher 
molecular mass and their physico-chemical characteristics 
the transport across the cellular membrane of TMZ-NLS 
peptide conjugates is still poor. Therefore a carrier molecule 
is needed, which can – after the transmembrane passage 
into the cytoplasm – discharge its TMZ-NLS-Cys cargo so 
that a sufﬁ  cient concentration of pharmacologically active 
molecules can reach their target site in the nucleus.
In this context numerous viral (Tabin et al 1982; Seymour 
1992; Advani et al 2002; Conlon and Flotte 2004; Palmer 
and Ng 2005) and non-viral (Bangham and Papahadjopoulos 
1966; Derossi et al 1996; Storm and Crommelin 1997; Vives 
et al 1997; Bourne et al 2000; Merdan et al 2002) well-
documented transport vehicles were designed by different 
laboratories. They are able to facilitate the cellular transport 
of molecules with inappropriate physico-chemical properties 
for the transmembrane passage.
Our considerations for improving the transport of TMZ 
into the cell nucleus led to a search for suitable ligation modes 
of TMZ with a nuclear address peptide (a) which in turn is 
connected to carrier molecules (b) (Table 1).
A brief comment is required here for a better understand-
ing of the following paragraphs. In chemistry the meaning 
of “ligation reaction” is the basis of Diels-Alder chemis-
try, on which we focus here, in contrast that in molecular 
biology, in which it means the ligase-catalized connection 
of nucleic acids at the 3’-hydoxy group and the 5’-phosphate 
terminus.
This ﬁ  rst ligation (a) should permit a multi-modular con-
nection of functional peptides and formation of higher peptide 
chain lengths compared to the different manufacturing tech-
niques. It should also achieve a higher functional variability 
regarding the coupled peptides or substances in relation to 
mono-modular peptides generated by simple solid phase 
peptide synthesis or by recombinant chemistry. However 
the fast and selective covalent linkage of biologically active 
molecules under physiological conditions still represents a 
great challenge in the chemical praxis.
For this reason, such a ligation reaction should meet the 
following criteria:
(1) rapid course of the reaction, (2) independent of solvent 
properties, (3) no side reaction with other functional groups 
present in the molecule, (4) no special coupling-reagents, 
(5) an economical procedure, and (6) irreversible chemical 
reaction characteristics. The following ligation methods are 
favorable:
Enzymatic methods
The enzyme-mediated peptide ligation method is favorable 
to preserve native active structures of proteins and peptides 
(Anthony-Cahill and Magliery 2002). In this context the bac-
terial enzyme sortase (Mazmanian et al 1999) demonstrates 
an interesting approach: a transpeptidase that catalyzes a 
sequence-speciﬁ  c ligation of functional peptides harboring 
the ligand motif Gly-Gly-Gly to the amino terminus of the 
target molecule or peptide (Parthasarathy et al 2007).
Chemical methods
The ‘Staudinger ligation’, which is based on the reaction of 
phosphines with azides under nitrogen elimination, is pro-
posed as a further convenient candidate for ligation reactions 
(Kohn and Breinbauer 2004; Chandra et al 2006). The second 
chemical reaction useful for ligation is the thioester-method, 
which has been described by different groups (Camarero et al 
2004; Yeo et al 2004). A method recently described demon-
strates a ligation of α-ketoacids and N-alkylhydroxylamines 
under production of CO2 and water as by-products (Bode et al 
2006). A further concept, the modular ‘click chemistry’, uses 
the most practical and reliable chemical transformations and 
could be considered a promising platform. Its applications are 
increasingly found in all aspects of drug discovery, ranging 
from offering valuable clues in combinatorial chemistry and 
target-templated in situ chemistry, to proteomics and DNA 
research, using bioconjugation reactions (Kolb et al 2001; 
Kolb and Sharpless 2003). In this concept the 1,3-dipolar 
cycloaddition, considered as ‘cream of the crop’ (Rostovtsev 
et al 2002), represents a prime example of the electrocyclic 
reactions developed by Huisgen (Huisgen 1984).
Method used in our experiments
Our ligation approach is based on cycloaddition reactions 
via the pericyclic Diels-Alder reaction (DAR) with ‘inverse-
electron-demand’, which is a modiﬁ  cation of π-electron-
deﬁ  cient N-heteroaromatics with electron-rich dienophiles 
(Bachmann and Deno 1949). The main open question was 
how to circumvent the reversibility of conventional DAR. 
Here we used tetrazine-structures harboring electron-pure 
dienes permitting an irreversible reaction by formation of 
molecular nitrogen (Kim et al 2005).
We reveal how proper chemistry contributes to optimi-
zation of pharmacological properties of an already efﬁ  cient 
drug such as TMZ, thereby possibly extending the spectrum 
of tumor entity treatments.Drug Design, Development and Therapy 2008:2 291
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Because the bimodal radiochemotherapy with TMZ is 
classiﬁ  ed as a standard treatment approach after primary 
diagnosis, we focused primarily on improving the estab-
lished pharmaceutical TMZ by coupling it to the modular 
structured carrier, termed here as the TMZ-BioShuttle, and 
by testing its dramatically increased efﬁ  ciency in different 
glioblastoma cell lines.
Experimental
All reactions and procedures were carried out under normal 
atmospheric conditions. Table 1 shows the schematic 
modules, Table 2 the educts, the intermediates and the 
products, and Table 3 the active substances investigated.
Solid phase peptide synthesis
of the K(TCT)-NLS-S∩S-BioShuttle 
transporter
Syntheses of the transport module and the NLS 
module linked with lysine (TCT)
For solid phase synthesis of the K(TCT)-NLS-S∩S-transport 
peptide we employed the Fmoc-strategy in a fully automated 
multiple synthesizer (Syro II) (Merrieﬁ  eld 1963). The  synthesis 
Table 1 Schematic pattern of the TMZ-NLS and transport-peptides modules (modular schemata of the TMZ-BioShuttle)     
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The table depicts the transmembrane transport module (lower part of the table) and the nuclear localization sequence (NLS) connected with the modified dienophile 
component tetracyclo-[5.4.21,7.O2,6.O8,11]3,5-dioxo-4-aza-9,12-trideca-diene (TCT) via the ε-amino coupling of the lysine (upper part of the table).  
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TMZ-Cargo with Diene-
Tetrazin-Spacer
Address-peptide with
dienophile
Cleav.
spacer 
Transmembrane
transport-peptide
-S∩S- CRQIKIWFQNRRMKKWKK
**)
MW: 513 MW: 3756
*) Tetracyclo-[5.4.2
1,7.O
2,6.O
8,11]3,5-dioxo-4-aza -9,12-tridecadiene
**) amino acids single letter code
Table 2 Educts for inverse-electron-demand-DAR and for the TMZ Cargo/K(TCT)-NLS-S∩S-BioShuttle
The left part of the table shows the amide-group modified temozolomide connected by epsilon-amino lysine to a tetrazine which acts as dien component. 
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Table 3 Chemical structures of the investigated active alkyla ting substances
The chemical structures of the TMZ-BioShuttle is shown in the upper part of the table. The lower part 
shows the graphic formula of the alkylating agent temozolomide.   Drug Design, Development and Therapy 2008:2 293
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was carried out on a 0.05 mmol Fmoc-Lys(Boc)-polystyrene 
resin 1% crosslinked and on a 0.053 mmol Fmoc-Cys(Trt)-
polystyrene resin (1% crosslinked). 2-(1H-Benzotriazole-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU) was used as coupling agent. The last amino acid of 
the NLS-peptide was incorporated as Boc-Lys(TCT)-OH. 
Cleavage and deprotection of the peptide resin were achieved 
by treatment with 90% triﬂ  uoroacetic acid, 5% ethanedithiol, 
2.5% thioanisol, and 2.5% phenol (v/v/v/v) for 2.5 h at room 
temperature. The products were precipitated in ether. The 
crude material was puriﬁ  ed by preparative HPLC on an 
Kromasil 300-5C18 reverse phase column (20 × 150 mm) 
using an eluent of 0.1% triﬂ  uoroacetic acid in water (A) and 
60% acetonitrile in water (B). The peptides were eluted with 
a successive linear gradient of 25% B to 60% B in 40 min 
at a ﬂ  ow rate of 20 mL/min. The fractions corresponding to 
the puriﬁ  ed protein were lyophilized.
Coupling of the transmembrane transporter-
and the K(TCT)-NLS-C-modules
As a last step the K(TCT)-NLS-C and the transport pep-
tide were oxidized in an aqueous solution of 2 mg/mL in 
20% DMSO for about 5 hours. The oxidation progress was 
monitored by analytical C18 reversed-phase HPLC, and then 
peptide was puriﬁ  ed as described above. The puriﬁ  ed material 
was characterized with analytical HPLC and laser desorption 
mass spectrometry in a Bruker Reﬂ  ex II.
The empirical formula of the K(TCT)-NLS-C module is 
C64H110N18O12S with a MW 1355,74.
Ligation chemistry of the K(TCT)-NLS-
S∩S-BioShuttle and the TMZ-derivative
TMZ-(amino-bond)-tetrazolin-spacer linkage
with the BioShuttle-carrier
A 0.2 mol preparation with 42.7 mg L1834 and 67.4 mg 
L1932 as well as 28 μL triethylamin were dissolved in chlo-
roform. The reaction process runs undisturbed and provides 
a deﬁ  ned product with the molecular weight (MW) m/e 513. 
Further preparation: 0.3 mmol L1932 Triﬂ  at MW 445 and 
0.4 mmol L1834 were dissolved in 100 μL triethylamin 
0.7 mmol overnight at room temperature. Thin-layer 
chromatography (TLC) (9.5/0.5 chloroform/EtOH) indicates 
a deﬁ  ned product which points to the complete reaction.
TMZ-dien-spacer linked with K(TCT)-NLS-S∩S-BioShuttle
Preparation of 0.2 mmol (48 mg F77 and 44 mg L1834) with 
0.2 mmol (0.03 mL) triethylamin: After dissolving the F77 
in triethylamin and chloroform, the acid chloride of L1834 
was added. The chemical reaction was carried out overnight 
at room temperature and the product was detected by TLC. 
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Figure 1 Mass spectrometry plot of the TMZ-BioShuttle (as shown in Table 3) demonstrates the estimated molecular mass. The ordinate represents the absolute intensity 
(a.i.); the abscissa the mass to charge ratio (m/z).Drug Design, Development and Therapy 2008:2 294
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By mass spectrometry we detected the mass of the chemical 
compound 4242.
Reagents and cell culture
Human glioblastoma (GBM) primary cells (Glio98 and 
Glio366) were provided by the DKFZ division of Biophysics 
of Macromolecules. All cell lines were cultured in DMEM 
(Gibco Cat. No. 12800) supplemented with 10% FCS and 
maintained in culture at 37 °C with 5% CO2 atmosphere and 
95% humidity.
Chemotherapy treatment
Pure temozolomide (TMZ) was purchased from Sigma-
Aldrich, Germany (Cat. No. 76899) and the material was 
subdivided into two parts for subsequent processing. One part 
was followed up and coupled to the transporter molecules. As 
a control, the second part was dissolved in acetonitrile 10% 
(Sigma-Aldrich, Germany) with a ﬁ  nal concentration of 0.2% 
acetonitrile. Further control studies with acetonitrile were 
performed to exclude potential toxic effects of acetonitrile.
Glio98 and Glio366 cells were suspended (1 × 105 cells/mL) 
in DMEM (control) and in DMEM containing appropriate 
amounts of TMZ and the TMZ-BioShuttle (50 μM equimo-
lar) and cell behavior was investigated for up to 6 days of 
induction time.
Cell cycle and cell death analysis
The effects on cell viability and cell cycle distribution were 
determined by DNA ﬂ  ow cytometry. Flow cytometric analyses 
were performed using a PAS II ﬂ  ow cytometer (Partec, Muenster, 
Germany) equipped with a mercury vapor lamp (100 W) and 
a ﬁ  lter combination for 2,4-diamidino-2-phenylindole (DAPI) 
stained single cells. From native probes the cells were iso-
lated with 2.1% citric acid/0.5% Tween 20 according to the 
method for high resolution DNA and cell cycle analyses 
(Ehemann et al 2003) at room temperature with slight 
shaking. Phosphate buffer (7.2 g Na2HPO4 × 2H2O in 100 mL 
H2O dest.) pH 8.0 containing DAPI was used for staining 
the cell suspension. Each histogram represents 30,000 cells 
for measuring DNA-index and cell cycle. For histogram 
analysis, we used the Multicycle program (Phoenix Flow 
Systems, San Diego, CA).
Cell viability – assessed by ﬂ  ow cytometry
with the PI-method
For detection of apoptotic cells and viability, a FACS Cali-
bur ﬂ  ow cytometer (Becton Dickinson Cytometry Sys-
tems, San Jose, CA) was used with ﬁ  lter combinations for 
propidium iodide. The Cellquest program (Becton Dickinson 
Cytometry Systems, San Jose, CA) was used for analyses 
and calculations. Each histogram and dot plot represents 
10,000 cells. After preparation according to Nicoletti et al 
(1991) with modiﬁ  cations (Singer et al 2007; Tschaharganeh 
et al 2007), measurements were acquired in the logarith-
mic mode in Fl-3 and calculated by setting gates over the 
ﬁ  rst three decades to detect apoptotic cells. Dead cells are 
positive for propidium iodide and stained red; living cells 
remain unstained. In the logarithmic histogram the positions 
of unstained living cells are in the ﬁ  rst 2 decades, the 3rd 
decade contains cells with membrane damage, and dead cells 
are placed in the 4th decade.
Results
Time-course of cell growth and cell 
death in Glio98 and Glio366 cells 
induced by TMZ and TMZ-BioShuttle – 
pharmacological effects
Two different glioma cell lines, herein referred as Glio98 
(Figure 2a-e, left column) and Glio366 (Figure 2a–e, right 
column) were used to investigate the effect of TMZ and 
TMZ-BioShuttle on brain tumor cells. After 24 hours of treat-
ment with the TMZ-BioShuttle, no change in the phenotype 
of both glioma cell lines could be observed under the light 
microscope (data not shown); however in the cell culture 
medium an increasing number of aggregated cells could be 
observed. In our opinion after 72 hours of treatment with 
TMZ cells a possible reconstitution of the phenotype was 
shown and also a regrowth 144 hours after TMZ treatment 
(Figure 2e). The cells treated with the TMZ-BioShuttle 
seemed not to regenerate.
After 144 hours of treatment with the TMZ-Bioshuttle 
an increase of aggregated Glio366 cells and of smaller scale 
aggregations in Glio98 cells in the cell culture medium were 
observed (not visible in the picture). Both adherent cells types 
reveal a non-conﬂ  uent state because of many dead cells in the 
TMZ-treated probes. The cell density declines dramatically 
from 72 to 144 hours after TMZ-BioShuttle treatment in both 
glioma lines but the decrease of adherent cells was greater in 
Glio366 cells than in Glio98 cells (Figure 2c).
To learn more about the cell death in the two treated 
glioma cells after treatment, we carried out comet assays 
in parallel probes (compared to Figure 2). Basically the 
Glio98 and Glio366 cells did not exhibit fragmented DNA; 
no comets of the Glio98 cells 72 hours after treatment with 
TMZ (Figure 3d) and TMZ-BioShuttle (Figure 3b) can be Drug Design, Development and Therapy 2008:2 295
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Figures 2a–e Microscopical monitoring of the treated glioblastoma cells.Drug Design, Development and Therapy 2008:2 296
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observed and they resembled the untreated Glio control cells 
(Figures 3a in both cell lines).
After 144 hours of treatment with TMZ (Figure 3e) the 
glioblastoma cells show different-sized and fragmented dead 
cells and comet structures. The shape of the two observed 
comets was not used for calculation since it was not a major 
event. The TMZ-BioShuttle treated cells are mainly swol-
len (Figure 3c). Furthermore, the total cell density of the 
TMZ-only treated samples was lower, compared with that 
in control and TMZ-BioShuttle treated samples. The comet 
assay study detected no DNA fragmentation in the Glio98 
and the Glio366 until 72 hours after treatment. 144 hours after 
application of TMZ-BioShuttle large amounts of cell frag-
ments could be observed in all treated cell lines (Figure 3c). 
DNA fragments could be detected in Glio366 (Figure 3e 
right column) but comets in the Glio98 cells are not visible 
144 hours after TMZ treatment (Figure 3e left column).
Cell cycle study
As can be seen in the next experiment the predominant event 
was discovered in the cell cycle investigation. Flow cytom-
etry is considered to be a valuable tool for high throughput 
measurements of the cell cycle, cellular dynamics, cell 
activities and cell toxicity studies. It provides sensitive and 
speciﬁ  c data on the cellular behavior of glioblastoma cells 
after treatment with TMZ and the TMZ-BioShuttle conju-
gate. We determined the cell cycle behavior of glioma cells, 
for example, of the Glio366 cells after drug treatment. To 
investigate the inﬂ  uence of TMZ with and without BioShuttle 
transporter we performed a time-course analysis of the cell 
cycle. Cell growth after drug treatment was dramatically dif-
ferent. The pharmacological effect on brain tumor cells was 
shown 144 hours after treatment with TMZ-BioShuttle.
Figure 4 shows cell cycle distribution of Glio366 cells 
144 hours after treatment: The plots named control, TMZ-
BioShuttle, and TMZ are shown from left to right. The cell 
cycle distribution is indicated as G1-phase, S-phase and the 
G2/M phase. These cells show a diploid cycle (red colored). 
The plot of the untreated control is shown (Figure 4, left) and 
exhibits a G1 cell fraction of 79% and a G2 cell fraction of 
10%. The contingent of cells in the S-phase amounts to 11%. 
Compared to the S-phase fraction of untreated control the per-
centage of S-phase cells treated with TMZ is decreased to 8%. 
The TMZ-BioShuttle treated Glio366 cells clearly exhibit a 
decreased amount of cells in the S-phase (2%). Compared 
to control, the TMZ and the TMZ-BioShuttle treated probes 
display an increased cell number in the G2/M phase of 20% 
and 72%, respectively. The cells in the G1-phase of the 
TMZ probe decreased slightly (72%) whereas in cells in 
the G1-phase of the TMZ-BioShuttle treated Glio366 cells 
decreased signiﬁ  cantly (26%) as shown in Table 4. The 
amount of debris (blue colored) is visible and each histogram 
represents 30,000 measured cells.
Cell viability study on human Glio98 Glio366 cells
The cell killing effect of TMZ and the TMZ-BioShuttle on the 
glioblastoma cell lines Glio98 and Glio366 is demonstrated 
in Figure 5 and in the corresponding values implemented in 
the Table 5.
The pharmacological effect of the TMZ-BioShuttle on 
Glio366 and Glio98 cells differs greatly from that of the 
non-derivatized TMZ.
The cell lines show a different sensitivity to chemo-
therapy with TMZ and TMZ-BioShuttle respectively. After 
72 hours of  treatment with TMZ-BioShuttle, 28% of Glio366 
cells were dead; after 144 hours of TMZ-BioShuttle treat-
ment 32.5% of the Glio366 cells were dead. The effect of 
TMZ on the Glio366 cell line was less noticeable compared 
to control. Dead cells at 72 hours after TMZ treatment are 
in the range of untreated controls (Glio366: 4.5% increases 
to 7%) after 6 days. The percentage of dead cells after TMZ 
treatment was decreased slightly (by 3.5%). 144 hours after 
TMZ treatment no difference was detectable between per-
centage of dead control cells and treated cells (7.5%). The 
percentage of dead cells is an underestimation because many 
cells were already degraded (Figure 2c).
The sensitivity of the investigated Glio98 cells to TMZ 
and TMZ-BioShuttle is somewhat different from that of 
Glio366 cells. Percentage of dead Glio98 control cells 
increased from 2.5% (3 days) to 10.5% (6 days). Three 
days after TMZ treatment, the relative amount of dead 
cells barely differed from the corresponding control cells 
(3.5%). Six days after TMZ treatment the amount of dead 
cells increased to 14.5%. After 3 days of TMZ-BioShuttle 
treatment Glio98 cells exhibit 13.5% dead cells, and 22% 
after 6 days of treatment.
Discussion
Treatment of high-grade gliomas poses a substantial chal-
lenge to neuro-oncologists. The main problems are positions 
of the tumors in the cerebrum, which allow a radical excision 
only in a limited number of patients, and a high recurrence 
rate after excision. Current available chemotherapy (nitro-
soureas, procarbazine and vincristine or the PCV protocol) 
is now at least 25 years old and even when combined with 
radiotherapy has not changed the fatal prognosis for patients Drug Design, Development and Therapy 2008:2 297
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Figure 3a–e Comet assay studies of untreated cells, treated with TMZ and TMZ-BioShuttle for different cell lines; the scale bar represents 20 μm.Drug Design, Development and Therapy 2008:2 298
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with high-grade glioma; also, progression-free survival in 
patients with glioblastoma multiforme has been greatly 
improved. Therefore, the initial reports of a substantial 
antitumor activity of temozolomide (TMZ) in brain tumors 
demonstrated by Newlands et al could indicate a relief 
(Newlands et al 1992). TMZ, a DNA-methylating agent 
of the imidazotetrazine class, was developed in the 1980s, 
through rational drug design (Denny et al 1994; Newlands 
et al 1997).
With regard to undesired side-effects like the often-
observed strong suppression of the peripheric lymphocytes, 
the connection of the ‘old fashioned’ TMZ drug as a cargo 
to transporter molecules (TMZ-BioShuttle) was investigated. 
These peptides, designed for facilitating rapid transport 
across cellular membranes, could improve their delivery and 
their targeting under the pharmacological activity in cells and 
tissues protecting cells in the bloodstream.
The treatment of glioblastoma Glio366 cells with TMZ 
interferes with the cell cycle and results in a decreased 
number of cells in the S-phase fraction as shown 144 hours 
after TMZ application (11% in the control and 8% in the TMZ 
treated cells). Furthermore, in the TMZ-BioShuttle treated 
cells the smallest contingent of the S-phase cells of 2% was 
detectable (Figure 4 and Table 4) after 144 hours.
The fact that the glioblastoma cells arrest in the G2/M-
phase after TMZ-treatment was documented by Hirose 
et al (2003) and could be not be conﬁ  rmed by the tested 
Glio366 cells, but the treatment with TMZ-BioShuttle clearly 
increased cell number residing in the G2/M-phase by up to 
72%. The increase seems to be attributable to interactions 
of TMZ and TMZ-BioShuttle with the mitogen-activated 
protein (MAP) kinase p38α, which is activated by the 
mismatch repair system (MMR) and is responsible for the 
TMZ-induced G2/M block (Hirose et al 2003).
The phenomenon of a slightly reduced S-phase (8% 
versus control 11%) in the TMZ treated Glio366 cells is not 
contradictory to the common effects of alkylating agents 
which retard rate of cell division (Bignold 2006). A possible 
explanation for the strongly decreased S-phase cell number in 
the TMZ-BioShuttle treated probes would be the existence of 
a S-phase cell cycle arrest as documented in a bimodal TMZ/
interferon-β (IFN-β) study (Park et al 2006). Our ﬂ  ow cytom-
etry experiments also showed a strong cell cycle arrest in the 
S-phase (Thomas et al 1996). A further criterion for a pro-
longed late S/G2-phase suggests an implication of the histone 
acetyltransferase 1 (HAT1) which participates in recovering 
block-mediated DNA damage (Barman et al 2006).
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The figure shows FACS scans of Glio366 brain tumor cells treated for 144 hours with TMZ-BioShuttle (middle) and TMZ (right).
The left part of the picture displays the cell cycle distribution of the untreated control cells.      
    Debris  cells       Cells  in  the  G1  and  G2/M  phases 
Figure 4 Cell cycle of Glio366 cells after application of TMZ and TMZ-BioShuttle.
The ﬁ  gure shows FACS scans of Glio366 brain tumor cells treated for 144 hours with TMZ-BioShuttle (middle) and TMZ (right). The left part of the picture displays the cell 
cycle distribution of the untreated control cells.
Debris cells Cells in the G1 and G2/M phases.
Table 4  Relative amount of cells in the cell cycle 72 and 144 hours 
after TMZ and TMZ-BioShuttle treatment
Cell fraction Control TMZ-BioShuttle  TMZ
7
2
 
h
o
u
r
s G1 [%] 73 33 74
G2 [%] 19 17 16
S [%] 8 50 10
1
4
4
 
h
o
u
r
s G1 [%] 79 26 72
G2 [%] 10 72 20
S [%] 11 2 8
The table is derived from the FACS scan data and shows an overview of the cell cycle 
distribution of Figure 5 calculated as a percentage. Drug Design, Development and Therapy 2008:2 299
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Figure 5 Flow cytometric estimation of cell killing of Glio366 (upper part) and of 
Glio98 cells (lower part. The abscissae of the graph show the relative amount of the 
dead Glio366 cells after 72 hours (black bars) and after 144 hours (gray bars) after 
exposure to the TMZ-BioShuttle (right bar-pair). The bars at the left site indicate the 
untreated control cells and the bar pair in the middle, the dead cells, TMZ-treated. 
The ordinates represent the relative amount of dead cells (%).
After exposure to the TMZ-BioShuttle for 144 hours, the 
observed strong increase of the G2-phase cells of Glio366 
cells could possibly originate from the documented inhibi-
tion of the RNA and protein syntheses, which are necessary 
for the successful completion of G2 and the initiation of 
mitosis. These G2-arrested cells were found to be deﬁ  cient 
in certain proteins that may be speciﬁ  c for the G2-mitotic 
transition (Rao 1980). Obstruction of the cell cycle process   
results in the decrease of the G1-phase cell fraction (26%) 
of the TMZ-BioShuttle treated Glio366 cells, which appears 
to be a consequence of their disability passing in the mitotic 
process.
The fact that TMZ is also known to induce a transient 
proliferation arrest combined with the accumulation of 
cells in the G2/M phase could be conﬁ  rmed as shown in the 
decrease of the cells in the S-phase and in turn by the increase 
of cells in the G2/M-phase from 10% (control) to 20%. In 
parallel a decrease of the G1-phase cells (72%) compared to 
the control (79%) could be observed also in the Glio366 after 
6 days. The conditioning to the cell cycle of the untreated 
control cells and cells 6 days after TMZ application could 
be a process described as potentially dependent on the p53 
status (Hirose et al 2001). It is documented that in glioma, 
p53 wild-type cells undergo prolonged cell cycle arrest 
associated with elevation of p53 levels, and although the 
cells are non-proliferative, they remain viable. Conversely, 
p53-deﬁ  cient cells undergo a more transient cell cycle arrest 
and within 12 days lose viability by mitotic catastrophe 
and/or apoptosis. Preclinical models demonstrated a sched-
ule-dependent antitumor activity against high-grade glioma, 
suggesting increased activity with repeated exposure to TMZ 
(Raymond et al 1997).
Further, the activity of the O6-methylguanine-DNA-
methyltransferase (MGMT) is involved in the DNA-repair-
procedures in cells. The epigenetic silencing of the MGMT 
DNA-repair gene is associated with longer survival in glio-
blastoma patients and beneﬁ  ts from alkylating agents like 
TMZ (Hegi et al 2005). Possibly after treatment, the cell cycle 
behavior of the Glio366 could be explained with epigenetic 
properties like CpG island hypermethylation of the DNA 
repair enzyme MGMT. The restricted TMZ activity and the 
crucial role of the repair enzyme MGMT are documented 
in the literature (Antoun et al 2000; Walton et al 2008). 
Here we did not consider to which extent the enrichment of 
pharmacological DNA-active methylating substances like 
TMZ could contribute to overcoming the opposite effects. 
If and to what extent MGMT effects are involved remains 
to be seen in further studies.
Figure 5 shows a dramatically increased sensitivity of 
both the Glio98 and the Glio366 cells to TMZ compared 
Table 5 Relative amount of dead Glio366 and Glio98 cells [%]
After 72 hours After 144 hours
control TMZ TMZ-BioShuttle control TMZ TMZ-BioShuttle
Glio366 4.5 3.5 28 7.5 7.5 32.5
Glio98 2.5 3.5 13.5 10.5 14.5 22
Actual amount of killed cells derived from Figure 5.Drug Design, Development and Therapy 2008:2 300
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with the TMZ-BioShuttle. The present data document a 
different cellular contumaciousness to TMZ treatment. 
A real effectiveness of the pure TMZ in Glio366 and 
Glio98 cells could not be observed, whereas clear cell 
killing effects caused by TMZ-BioShuttle were detected 
in contrast.
It is important to note that the TMZ-BioShuttle treatment 
of Glio366 and Glio98 glioma cells redounds to cell killing 
effects as shown in Figure 5 and Table 5. In the TMZ treated 
Glio366 probes dead cells barely differered from their ratio 
in the untreated cells after 3 days (3%–4%) as well as after 
6 days (9%) after TMZ application, but the percentage of 
dead cells treated with TMZ-BioShuttle escalated to 28% 
after 3 days and 32.5% after 6 days.
Furthermore the novel properties of the TMZ-BioShuttle 
could give reason to the enlargement of other tumor entities 
like the therapy of prostate tumors.
The application of the TMZ-BioShuttle could minimize 
the handicap of TMZ for the therapy of patients with brain 
tumors but the establishment of the TMZ-BioShuttle neces-
sitates new ways for the synthesis. Conditions that ham-
pered the above postulated criteria such as rapid and whole 
concurrent chemical reactions in aqueous solution at room 
temperature for a proper chemical ligation of functional 
peptides could be circumvented using the ‘inverse-electron-
demand’ of the Diels-Alder reaction. This reaction enhances 
the economics of the chemical reaction by the following 
parameters: the increase in the reaction rate, gentle reaction 
conditions at room temperature and the resulting reaction 
kinetics demand no excess at all in the educts. Furthermore 
this careful execution of the chemical reaction could real-
ize the ligation of pharmacologically active but sensitive 
and highly unstable pharmaceutical ingredients without 
functional deprivation. The potential of the TMZ modiﬁ  ed 
by coupling to the BioShuttle carrier (TMZ-BioShuttle) 
has been conﬁ  rmed for the treatment of brain tumors and 
remains an attractive drug for further clinical combination 
chemotherapy.
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